What is the current cash runway and burn rate, and when does the company anticipate needing additional financing?

Cash runway & burn rate

Serina disclosed that it ended Q2 2025 with ≈ $71 million of cash and cash equivalents. The company’s operating cash‑burn for the quarter was ≈ $23 million, which translates to an average burn rate of roughly $9 million per month (≈ $108 million on a 12‑month basis). At that burn rate, the existing cash balance gives the company approximately 12–13 months of runway.

Financing outlook

Management indicated that, given the current burn trajectory, additional financing will be required by the end of 2025 (approximately Q4 2025) to fund ongoing clinical development of SER‑252, the POZ‑Platform expansion, and general corporate needs. The company plans to evaluate a combination of equity, debt, or strategic partnership financing at that time.

Trading implications

A 12‑month runway for a clinical‑stage biotech is modest but typical for a company in SER‑252’s late‑stage development phase. The looming financing need creates a near‑term catalyst that could increase volatility: a successful equity raise or strategic partnership may buoy the stock, while any delay or dilution‑heavy financing could pressure the share price. Traders should monitor upcoming 10‑Q filings and any forward‑looking guidance; a clear financing plan (e.g., a priced public offering) could serve as a bullish catalyst, whereas a prolonged financing gap could trigger downside pressure. Technicals show the stock near a key resistance level; a breakout above it could signal confidence that financing will be secured on favorable terms. Conversely, a break below the recent support level may reflect market skepticism about the company’s ability to raise capital without significant dilution.